NCT01388088

The Effect of Amiloride and Spironolactone in Patients With Hypertension

Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Erling Bjerregaard Pedersen · Academic / Other
• Sex: All
• Age: 45 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone. The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.

Detailed description

Purpose of the study is to examine the effect of amilorid and spironolacton on 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsewavevelocity, augmentation index and centralt bloodpressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory blood pressure

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Spironolactone	25 mg twice a day
DRUG	Amiloride	5 mg twice a day
DRUG	Placebo	twice a day

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2011-07-06
• Last updated: 2012-03-28

Locations

1 site across 1 country: Denmark